Thomas Smith
Stock Analyst at Leerink Partners
(2.33)
# 2,672
Out of 5,050 analysts
63
Total ratings
30.65%
Success rate
14.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RAPT RAPT Therapeutics | Upgrades: Outperform | $16 → $37 | $28.86 | +28.21% | 3 | Sep 26, 2025 | |
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $1.10 | -9.09% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $2.26 | +298.23% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $2.32 | +201.72% | 7 | Nov 19, 2024 | |
| ALMS Alumis | Initiates: Outperform | $29 | $4.72 | +514.41% | 1 | Jul 23, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $7.87 | +395.55% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $7.52 | +245.74% | 1 | Mar 25, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $105.27 | -81.00% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $854.65 | -49.10% | 3 | Mar 3, 2023 | |
| IRON Disc Medicine | Initiates: Outperform | $36 | $83.83 | -57.06% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $1.55 | +351.61% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $23.35 | -10.06% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $27.44 | +63.99% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $11.01 | -45.50% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $5.63 | +6.57% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $0.72 | +595.80% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $10.63 | +59.92% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $22.90 | +179.48% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $17.50 | +300.00% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $2.06 | +1,162.14% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $36.77 | -67.36% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $3.89 | +157.07% | 4 | Apr 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $4.95 | +7,980.81% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $16.20 | +393.83% | 2 | Dec 8, 2020 |
RAPT Therapeutics
Sep 26, 2025
Upgrades: Outperform
Price Target: $16 → $37
Current: $28.86
Upside: +28.21%
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $1.10
Upside: -9.09%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $2.26
Upside: +298.23%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $2.32
Upside: +201.72%
Alumis
Jul 23, 2024
Initiates: Outperform
Price Target: $29
Current: $4.72
Upside: +514.41%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $7.87
Upside: +395.55%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $7.52
Upside: +245.74%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $105.27
Upside: -81.00%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $854.65
Upside: -49.10%
Disc Medicine
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $83.83
Upside: -57.06%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $1.55
Upside: +351.61%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $23.35
Upside: -10.06%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $27.44
Upside: +63.99%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $11.01
Upside: -45.50%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $5.63
Upside: +6.57%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $0.72
Upside: +595.80%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $10.63
Upside: +59.92%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $22.90
Upside: +179.48%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $17.50
Upside: +300.00%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $2.06
Upside: +1,162.14%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $36.77
Upside: -67.36%
Apr 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.89
Upside: +157.07%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $4.95
Upside: +7,980.81%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $16.20
Upside: +393.83%